Dabigatran etexilate Recruiting Phase 4 Trials for Cardioembolic Events / Oral Anticoagulation / Nonvalvular Atrial Fibrillation Treatment

IndicationsStatusPurposePhase
RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02666157Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
NCT02331602Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran